Jpn. J. Pharmacol. 88 Supplement I (2002)

The 75th Annual Meeting

March 13-15, 2002
Kumamoto

Chairman: Takeshi Miyata

Abstracts

============================================================================================

Contents

Special Lectures

SL-1 Clinical pharmacogenetics and proposal on a tailor-made drug therapy
Takashi Ishizaki .......... 2P

SL-2 Studies on calcium signaling: CaM kinase cascade
Eishichi Miyamoto .......... 2P

SL-3 Regulatory mechanism of gastric acid secretion and mucosal integrity: an analysis with various gene deficient mice
Susumu Okabe .......... 2P

SL-4 Roles of calmodulin-dependent protein kinases in neuronal development and plasticity
Thomas R. Soderling .......... 2P

SL-5 Aquaporin water channels as target for drug discovery
Alan S. Verkman .......... 3P

SL-6 Roles of Rho family GTPases in the regulation of cytoskeleton and cell adhesion
Kozo Kaibuchi .......... 3P

SL-7 Role of IP₃ receptor in development and neural plasticity
Katsuhiko Mikoshiba .......... 3P

SL-8 Development of antithrombotic drugs: current status and future directions
Shin-ichiro Ashida .......... 3P

SL-9 Recent progress and challenges in chemotherapy of AIDS
Hiroaki Mitsuya .......... 4P

Award Lectures

AL-1 Rho-mediated signal transduction and its physiological roles
Toshimasa Ishizaki .......... 5P

AL-2 Mechanism of production and release of tumor necrosis factor-E´?
Izumi Hide .......... 5P

AL-3 Analyses of Ca-related ion channel currents and their involvement in Ca mobilization in smooth muscle and endothelial cells
Katsuhiko Muraki .......... 5P

Symposia

S-01 Pharmacogenomics: the frontiers of genome medicine .......... 8P

S-02 Calcium signaling and cell functions in the central nervous system .......... 9P

S-03 Regulatory role of mechanical stress response in cellular functionA°|development of new drugs and tissue engineering .......... 10P

S-04 Current progress on study of lower urinary tract function-from the standpoint of basic medicine and clinical medicine .......... 11P

S-05 Recent advances in the physiological and pathophysiological roles of NO and their clinical applications .......... 13P

S-06 Recent progress in function and regulation of neurotrophic factors .......... 14P

S-07 Roles of mitochondria in cardiac ischemia/reperfusion injury ........... 15P

S-08 Pharmacological approaches to develop anabolic drugs for bone formation-proposal of new targets for drug discovery .......... 16P

S-09 Development and application of chymase inhibitor .......... 18P

S-10 Virtual human: post-genome world .......... 19P

S-11 Regulation by protein phosphorylation of vesicle transport and exocytosis .......... 20P

S-12 Reactive oxygen species and cardiovascular disease .......... 22P

S-13 New development in traditional medicine research .......... 23P

S-14 PPARE´? as a new target for therapeutic strategy .......... 24P

S-15 Molecular regulation of central nervous system stem cells ....... 25P

S-16 New trends in stress research .......... 27P

S-17 Drug interaction and pharmacology .......... 28P

S-18 Pharmacological evaluation of the risk of drug-induced long QT syndrome .......... 29P

S-19 Functions of central nervous system through H1 receptors and the development of new drugs based on our new knowledge of these functions .......... 31P

S-20 Studies of the G-protein coupled receptors that require additional modifying proteins for their expression on the cell surface .......... 32P

S-21 Applications of and regulations on the use of human tissue in drug development .......... 33P

S-22 Investigations of the pathophysiological changes under the effect of histamine using gene disrupted mice .......... 35P

S-23 Linkage between therapeutic information and pharmacological aspects .......... 36P

S-24 Membrane transporters: their functional regulation and possible drug targets .......... 37P

S-25 Novel target molecules for drug development to treat genetic diseases and cancer .......... 38P

S-26 Inducible histamine and immunomodulation .......... 40P

S-27 Pharmacology of inverse agonists and neutral antagonists .......... 41P

S-28 Signal transduction by second messengers derived from membrane phospholipids .......... 42P

S-29 Contribution of pharmacology for new drug applications in Japan .......... 43P

S-30 Role of pharmacological education for clinical trials in Japan .......... 44P

S-31 Future prospects of pharmacogenomics in drug therapy .......... 46P

S-32 G protein-coupled receptors: their molecular structures and control of intracellular signalings .......... 47P

S-33 Optical bioimaging and drug development .......... 49P

S-34 Mucoactive drug research: future prospects (International Symposium) .......... 50P

S-35 Stress and vascular diseases .......... 51P

S-36 Polarized distribution and functional regulation of membrane proteins involved in vectorial transport in epithelial cells .......... 52P

S-37 Physiology of the G protein-coupled protease receptor PAR (protease-activated receptor) .......... 53P

S-38 Basic and clinical aspects of arachidonate lipoxygenase metabolism .......... 55P

S-39 Physiology of lung epithelium and its regulation .......... 56P

S-40 Recent advances in cardiac protection .......... 58P

S-41 New aspects of the medulla oblongata and spinal cord as a basis of life: applications of this new knowledge for drug development .......... 59P

Poster Sessions

Cardiovascular pharmacologyA°EHematology (I) .......... P-001 - P-076
Central nervous system pharmacology (I) .......... P-077 - P-146
Gastrointestinal pharmacology .......... P-147 - P-174
Bone and dental pharmacology .......... P-175 - P-194
ImmunopharmacologyA°EInflammation .......... P-195 - P-254
Respiratory pharmacology ......... P-255 - P-277
Chemotherapy .......... P-278 - P-284
Toxicology .......... P-285 - P-294
Biogenic active substances .......... P-295 - P-353
ReceptorsA°EChannelsA°ETransport systems (I) .......... P-354 - P-405
Intracellular signaling .......... P-406 - P-463
Biochemical pharmacology .......... P-464 - P-507
Central nervous system pharmacology (II) .......... P-508 - P-570
Renal pharmacology .......... P-571 - P-593
ReceptorsA°EChannelsA°ETransport systems (II) .......... P-594 - P-654
Peripheral nervous system pharmacology .......... P-655 - P-685
Central nervous system pharmacology (III) .......... P-686 - P-745
Smooth muscle pharmacology .......... P-746 - P-783
Cardiovascular pharmacologyA°EHematology (II) .......... P-784 - P-854
Endocrine pharmacology .......... P-855 - P-870
Clinical pharmacology .......... P-871 - P-891

Author Index
Subject Index

============================================================================================

Subscription/back issue orders: to Subscription Information

Copyright The Japanese Pharmacological Society